摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one | 183023-15-6

中文名称
——
中文别名
——
英文名称
(S)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one
英文别名
(S)-5,6-dihydro-2H-5-phenyl-1,4-oxazin-2-one;2H-1,4-Oxazin-2-one, 5,6-dihydro-5-phenyl-, (5S)-;(3S)-3-phenyl-2,3-dihydro-1,4-oxazin-6-one
(S)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one化学式
CAS
183023-15-6
化学式
C10H9NO2
mdl
——
分子量
175.187
InChiKey
DINGSFSTMYUIAU-SECBINFHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    38.7
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    Synthesis of enantiomerically pure α-amino acids via chemo- and diastereoselective alkylation of (5S)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one
    摘要:
    (5S)-5-苯基-5,6-二氢-2H-1,4-氧嗪-2-酮在路易斯酸介导下进行化学和立体选择性良好的Grignard试剂亲核加成反应,生成加成物。随后,该加成物可以通过简便的方法转化为光学纯的(S)-α-氨基酸。版权(C) 1997 Elsevier Science Ltd. 所有权利保留。
    DOI:
    10.1016/s0957-4166(97)00587-9
  • 作为产物:
    描述:
    (5S)-3,4,5,6-四氢-5-苯基-4(H)-1,4-恶嗪-2-酮N-溴代丁二酰亚胺(NBS)methyloxirane 作用下, 以 二氯甲烷 为溶剂, 反应 3.0h, 以55%的产率得到(S)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one
    参考文献:
    名称:
    Synthesis, isomerisation and diels-alder reactions of (5S)-5-phenyl-3,4-dehydromorpholin-2-one
    摘要:
    (5S)-5-苯基-3,4-去氢吗啉-2-酮[(5S)-5-苯基-5,6-二氢-2H-1,4-氧嗪-2-酮]2a 是通过一锅法溴化/脱氢溴化反应从(SS)-5-苯基吗啉-2-酮制备,并在具有区域和对映选择性的催化的Diels-Alder反应中发生反应。版权(C)1996 Elsevier Science Ltd。
    DOI:
    10.1016/0957-4166(96)00329-1
点击查看最新优质反应信息

文献信息

  • An Asymmetric Ugi Three-Component Reaction Induced by Chiral Cyclic Imines: Synthesis of Morpholin– or Piperazine–Keto-carboxamide Derivatives
    作者:Deguang Zhu、Liang Xia、Li Pan、Sheng Li、Ruijiao Chen、Yongren Mou、Xiaochuan Chen
    DOI:10.1021/jo2021967
    日期:2012.2.3
    4-oxazin-2-one substrates, as preformed cyclic aldimines and ketoimines, were employed to develop a new asymmetric Ugi three-component reaction for the first time. The Ugi reaction of the imines, isocyanides, and carboxylic acids opens an efficient access to novel morpholin-2-one-3-carboxamide compounds. The chiral imines showed promising stereoinduction for the new chiral center of the Ugi products, and
    一系列手性5,6-二氢-1,4-恶嗪-2-酮底物,如预先形成的环状醛亚胺和酮亚胺,首次用于开发新的不对称Ugi三组分反应。亚胺,异氰酸酯和羧酸的Ugi反应使人们可以有效地获得新型的吗啉-2-二-3-甲酰胺化合物。手性亚胺对Ugi产品的新手性中心显示出有希望的立体诱导,并且在大多数情况下获得了主要的反式异构体。添加一些路易斯酸或质子酸可以进一步提高非对映选择性,但通常会导致总收率下降。Ugi-3CR可以扩展到ketopiperazine-2-carboxamide衍生物的立体选择性合成。
  • An Efficient Procedure for the Synthesis of Morpholin-2-one-3-carboxamide Derivatives in Good Diastereoselectivity by the Ugi Reaction
    作者:Xiaochuan Chen、Deguang Zhu、Ruijiao Chen、Haibo Liang、Sheng Li、Li Pan
    DOI:10.1055/s-0029-1219533
    日期:2010.4
    series of 5-substituted morpholin-2-one-3-carbox-amide derivatives were efficiently synthesized by a Ugi three-component reaction involving chiral 5,6-dihydro[1,4]oxazin-2-one substrates, isocyanides and carboxylic acids. The newly formed chiral center in the product was obtained in good diastereoselectivity.
    通过涉及手性 5,6-二氢[1,4]恶嗪-2-one 底物、异氰化物和羧酸的 Ugi 三组分反应有效合成了一系列 5-取代吗啉-2-one-3-羧酰胺衍生物酸。产物中新形成的手性中心以良好的非对映选择性获得。
  • Allyl Silane Additions to Highly Electrophilic 5,6-Dihydro-2H-1,4- oxazinones
    作者:Cynthia Shafer、Julie Pigza、Tadeusz Molinski
    DOI:10.2174/157017809787893046
    日期:2009.4.1
    Allylsilane addition to the dihydro-2H-1,4-oxazinones, 1, proceeded in moderate to good yields with transdiastereoselectivity. The yield of addition reactions of 5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one with allylsilanes is improved over the corresponding additions of Grignard reagents to 1 and illustrates a simple path to protected β,β- disubstituted α-amino acids.
    烯丙基硅烷对二氢-2H-1,4-恶嗪酮 1 的加成反应具有中等至良好的产率和反式对映选择性。5-苯基-5,6-二氢-2H-1,4-恶嗪-2-酮与烯丙基硅烷的加成反应的收率比格氏试剂与 1 的相应加成反应的收率要高,说明了一种获得受保护的 β、β- 二取代 α-氨基酸的简单途径。
  • Synthesis, isomerisation and diels-alder reactions of (5S)-5-phenyl-3,4-dehydromorpholin-2-one
    作者:David Ager、Nicholas Cooper、Geoffrey G. Cox、Florence Garro-Hélion、Laurence M. Harwood
    DOI:10.1016/0957-4166(96)00329-1
    日期:1996.9
    (5S)-5-Phenyl-3,4-dehydromorpholin-2-one [(5S)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one] 2a is prepared by a one-pot bromination / dehydrobromination of (SS)-5-phenyl morpholin-2-one and undergoes regio- and diastereocontrolled catalysed Diels-Alder reactions. Copyright (C) 1996 Elsevier Science Ltd
    (5S)-5-苯基-3,4-去氢吗啉-2-酮[(5S)-5-苯基-5,6-二氢-2H-1,4-氧嗪-2-酮]2a 是通过一锅法溴化/脱氢溴化反应从(SS)-5-苯基吗啉-2-酮制备,并在具有区域和对映选择性的催化的Diels-Alder反应中发生反应。版权(C)1996 Elsevier Science Ltd。
  • Total Synthesis of Polydiscamides B, C, and D via a Convergent Native Chemical Ligation–Oxidation Strategy
    作者:Gajan Santhakumar、Richard J. Payne
    DOI:10.1021/ol502045u
    日期:2014.9.5
    The first total syntheses of the marine sponge-derived cyclic depsipeptide natural products Polydiscamides B, C, and D are described. The molecules were constructed through the convergent fusion of cyclic and linear fragments via an unprecedented native chemical ligation–oxidation protocol.
    描述了海洋海绵衍生的环状二肽天然产物Polydiscamides B,C和D的第一批合成。这些分子是通过前所未有的天然化学连接-氧化方案,通过环状和线性片段的融合融合而构建的。
查看更多

同类化合物

乙基6H-1,2-恶嗪-3-羧酸酯 6-乙氧基-6H-1,2-恶嗪-3-甲醛 6-乙氧基-3-苯基-6H-1,2-恶嗪 5-甲氧基-3,6-二氢-2H-[1,4]恶嗪 5-乙氧基-3,6-二氢-2H-1,4-恶嗪 5,6-二氢-2H-1,4-恶嗪-3-胺 4H-1,4-恶嗪 3H-咪唑并[2,1-c][1,4]恶嗪 3-甲基-5-苯基-2H-1,4-恶嗪 3,5-二苯基-2H-1,4-恶嗪 3,5,5,6-四甲基-5,6-二氢-2H-1,4-恶嗪-2-酮 2H-[1,4]恶嗪并[3,4-b][1,3]恶嗪 2H-1,4-恶嗪 2H-1,4-噁嗪-2-酮,5,6-二氢-5-(1-甲基乙基)-3-苯基-,(S)- 2H-1,4-噁嗪-2-酮,3-(1,1-二甲基乙基)-5,6-二氢-5-苯基-,(R)- 2H-1,3-恶嗪 2H-1,2-恶嗪 2-(二甲基氨基)-4-苯基-4H-1,3-恶嗪-5-甲醛 (5S)-5,6-二氢-6,6-二甲基-5-苯基-2H-1,4-恶嗪-2-酮 6-amino-4-phenyl-4H-1,2-oxazine-3,5-dicarbonitrile (2S,5R)-2-hydroxy-5,6-dihydro-2-ethyl-3-methyl-5-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-3-methyl-2,5-diphenyl-2H-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3,5-trimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-6-phenyl-2-propyl-2H-1,4-oxazine (Z)-methyl-2-((R)-5-(2-(methylthio)ethyl)-3-oxomorpholin-2-ylidene)acetate (Z)-methyl-2-((R)-5-benzyl-3-oxomorpholin-2-ylidene)acetate (2R,5R,6S)-5,6-dihydro-3,6-diphenyl-2-hydroxy-5-methyl-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine 2-heptafluoropropyl-3-trifluoromethyl-5,6-dihydro-1,4-oxazin-2-ol (2S,5R,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine 6H-1,2-Oxazine 4,4,6-Trimethyl-2-dimethylamino-4H-1,3-oxazine 3-(chloromethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 3-(acetoxymethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 6-Butyl-2,4-diphenyl-4H-[1,3]oxazine 2-methyl-2,4,6-triphenyl-2H-1,3-oxazine (S)-2,4,6-triphenyl-4H-1,3-oxazine 2-Isopropenyl-6-phenyl-6-piperidin-1-yl-6H-[1,3]oxazin-4-ol 5-methyl-6-perhydroxy-3-phenyl-6H-1,2-oxazine 5-methyl-3-phenyl-6-(prop-2-yn-1-oxy)-6H-1,2-oxazine 2,2,3,3,6,6-Hexafluoro-5-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-3,6-dihydro-2H-[1,4]oxazine 4,4-Dimethyl-2-phenyl-1,3-oxazine (R)-3-(but-3-enyl)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one Acetic acid 3,5-dimethyl-6-oxo-3,6-dihydro-2H-[1,4]oxazin-3-ylmethyl ester (2R,5R)-3-methyl-5-phenyl-2-(trifluoromethyl)-5,6-dihydro-2H-1,4-oxazin-2-ol